Insiders Seeing Green With FLXN At New 52-Week High

In trading on Thursday, shares of Flexion Therapeutics, Inc. ( FLXN) touched a new 52-week high of $22.00/share. That's a 191.01% rise, or $14.44 per share from the 52-week low of $7.56 set back on 03/17/2016. That means at today's intraday high, any investor who purchased FLXN stock any time over the past 52 weeks has an unrealized gain, including company insiders.

Over the past six months, insiders have been scooping up shares, and those bets are now paying off handsomely. As summarized by the table below, FLXN has seen 4 different instances of insiders buying over the trailing six month period.

START SLIDESHOW:
Ten Bargains You Can Buy Cheaper Than The Insiders Did »

Purchased Insider Title Shares Price/Share Value
05/16/2016 Neil Bodick Chief Medical Officer 1,250 $9.22 $11,525.00
05/16/2016 Frederick W. Driscoll Chief Financial Officer 2,500 $9.19 $22,971.75
05/16/2016 Michael D. Clayman President and CEO 2,000 $9.51 $19,025.00
05/17/2016 Frederick W. Driscoll Chief Financial Officer 2,500 $9.87 $24,668.00
05/17/2016 Michael D. Clayman President and CEO 2,000 $9.73 $19,465.00
05/17/2016 Neil Bodick Chief Medical Officer 800 $9.60 $7,680.00
05/17/2016 Michael D. Clayman President and CEO 2,000 $9.73 $19,465.00
05/17/2016 Neil Bodick Chief Medical Officer 800 $9.60 $7,680.00
05/18/2016 Michael D. Clayman President and CEO 2,000 $10.23 $20,465.00
05/18/2016 Neil Bodick Chief Medical Officer 2,100 $10.20 $21,420.00
05/19/2016 Michael D. Clayman President and CEO 2,000 $9.65 $19,297.20
05/19/2016 Neil Bodick Chief Medical Officer 850 $10.00 $8,500.00
05/20/2016 Michael D. Clayman President and CEO 2,000 $10.41 $20,810.40
06/08/2016 Barbara N. Lubash 714,285 $14.00 $9,999,990.00
06/08/2016 Ventures Iii, Llc Versant 714,285 $14.00 $9,999,990.00
06/14/2016 C. Ann Merrifield Director 1,000 $13.39 $13,387.00

The chart below shows where FLXN has traded over the past year, with the 50-day and 200-day moving averages included.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

2 Biotechs That Could Flex Their Muscles

Biotech Movers: Ocular, Alder, Flexion

2 Recovering Biotech Names With Room to Run